Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09IFW
|
|||
| Former ID |
DPR000033
|
|||
| Drug Name |
Cruentaren
|
|||
| Indication | Fungal infection [ICD-11: 1F29-1F2F; ICD-10: B35-B49; ICD-9: 110-118] | Preclinical | [1] | |
| Therapeutic Class |
Antifungal Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vacuolar-type proton ATPase catalytic A (v-ATPase-A) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Oxidative phosphorylation | |||
| Metabolic pathways | ||||
| Phagosome | ||||
| Synaptic vesicle cycle | ||||
| Collecting duct acid secretion | ||||
| Vibrio cholerae infection | ||||
| Epithelial cell signaling in Helicobacter pylori infection | ||||
| Rheumatoid arthritis | ||||
| Reactome | ROS production in response to bacteria | |||
| Insulin receptor recycling | ||||
| Transferrin endocytosis and recycling | ||||
| WikiPathways | Latent infection of Homo sapiens with Mycobacterium tuberculosis | |||
| Iron uptake and transport | ||||
| Signaling by Insulin receptor | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009). Rev Iberoam Micol. 2009 Mar 31;26(1):15-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.